9th Annual MSK Symposium on Lymphoma

2025 | April 25–26 Join Us In-Person or Virtually

Zuckerman Research Center | New York City Special In-Person-Only Sessions Early Rates Available Until February 28





Memorial Sloan Kettering Cancer Center

Overview

This annual symposium provides a comprehensive overview of the latest advancements in the evolving field of lymphoma. Renowned national and international experts present cuttingedge discoveries in lymphoma biology, state-of-the-art diagnostic techniques, and innovative treatment strategies.

The program highlights the clinical management of common lymphoma subtypes while also examining groundbreaking drug developments that are redefining patient care. Attendees will gain valuable insights into the latest findings in lymphoma biology and pathology, exploring how these breakthroughs are being translated into practical, impactful solutions for clinical practice.

Spanning a day and a half, this year's program features:

- **Keynote Lectures:** Featuring renowned leaders in lymphoma research and care.
- Interactive Panel Discussions: Practical discussions on innovative approaches to advancing patient outcomes.
- Empowering APPs and Nurses— Professional Development Breakout Session*: Tailored content for interprofessional teams, emphasizing their pivotal role in advancing lymphoma treatment.
- Networking Opportunities*: Connect with colleagues and faculty during breaks as well as a dedicated Welcome Reception on Friday evening and a Farewell Lunch Reception on Saturday afternoon.

*Available for in-person attendees only.

Register by February 28 for early rates: msk.org/LymphomaSymposium

AUDIENCE

The target audience includes internists, oncologists, hematologists as well as medical and radiation oncologists, hematopathologists, scientists, and medical trainees involved in the diagnosis, treatment, and biomedical research of lymphoma.



Participants are invited to join us either in person or virtually.

Zuckerman Research Center 417 East 68th Street New York, NY

SYLLABUS

Attendees will gain access to an online syllabus following the symposium, which will include select PDFs of faculty presentations (slides) and recorded videos. Please note, if you're unable to attend the Nursing and APP Breakout Session in person, it will be recorded and made available through the syllabus.

OBJECTIVES

At the conclusion of this symposium, attendees will be able to:

- Describe recent advances in lymphoma classification
- Discuss first line treatment options in most frequent lymphoma entities
- Describe new agents mode of actions, efficacy, and side effects
- Discuss options and recommendations for patients in the relapse refractory setting
- Provide adequate information to help shared decision with patients regarding their treatment

Register by February 28 for early rates: msk.org/LymphomaSymposium

MSK DIRECTOR



Gilles Salles, MD, PhD Chief, Lymphoma Service

MSK PLANNING COMMITTEE



Ahmet Dogan, MD, PhD Chief, Hematopathology Service



Kojo S.J. Elenitoba-Johnson, MD Chair, Department of Pathology and Laboratory Medicine



Lauren Drosick. PA-C Advanced Practice Provider



Sean E. Healton, MD, PhD Hematology/ Oncology Fellow



Steven Horwitz, MD

Attending, Lymphoma Service



Andrew Intlekofer, MD Assistant Attending,

Lymphoma Service



Alison J. Moskowitz. MD Associate Attending,

Lymphoma Service



Hans-Guido Wendel, MD Member/Professor, Cancer Biology and Genetics Program



Ariela Noy, MD Attending, Lymphoma Service

Joachim Yahalom, **MD, FACR, FASTRO** Attending, External Beam Radiotherapy Service



Andrew D. Zelenetz, MD, PhD Medical Director, Quality Informatics: Attending, Lymphoma Service

INVITED FACULTY

Christopher R. Flowers, MD, MS

MD Anderson Cancer Center Houston, TX

Georg Lenz, MD

Universität Münster Münster, Germany

Brian K. Link, MD

The University of Iowa Carver College of Medicine Iowa City, IA

Kami J. Maddocks, MD The Ohio State University

Columbus, OH

David G. Maloney, MD, PhD

Fred Hutchinson Cancer Research Center University of Washington Seattle, WA

Coraline Mlynarczyk, PhD Yale School of Medicine New Haven, CT

MSK FACULTY

Zachary Epstein-Peterson, MD

Assistant Attending, Lymphoma Service

Lorenzo Falchi, MD

Assistant Attending, Lymphoma Service

Brandon Imber, MD, MA

Assistant Attending, Department of Radiation Oncology

Anita Kumar, MD

Associate Attending, Lymphoma Service

Efrat Luttwak, MD, MPH Assistant Attending, Lymphoma Service

Barbara Pro, MD

Herbert Irving Comprehensive Cancer Center New York, NY

Laura Pasqualucci, MD

Columbia University New York, NY

Sandrine Roulland, PharmD, PhD

Centre d'Immunologie Marseille Luminy Marseille, France

Clémentine Sarkozy, MD, PhD

Institut Curie Paris, France

Margaret A. Shipp, MD

Dana-Farber Cancer Institute Harvard Medical School Boston, MA

Sarah Rutherford, MD

Weill Cornell Medicine New York, NY

Ivan Maillard, MD, PhD

Attending, Leukemia Service; Head of the Division of Hematologic Malignancies

Raphael Steiner, MD

Associate Attending, Lymphoma Service

Robert Stuver, MD

Assistant Attending, Lymphoma Service

Jasmine M. Zain, MD Attending, Lymphoma Service

Ting Zhou, MD Assistant Attending, Hematopathology Service

Friday • April 25

| Time | Session/Faculty | |
|----------------|---|--|
| 7:00 AM | In-person Attendee Breakfast and Check-in | |
| 7:55 AM | Virtual Attendee Zoom Sign On | |
| 8:00 am | Welcome and Introduction Gilles Salles, MD, PhD | |
| 8:10 am | PLENARY LECTURE Department of Medicine Grand Rounds CHAIR: Gilles Salles, MD, PhD | |
| | Epidemiology and Outcomes of Lymphoma Christopher R. Flowers, MD, MS | |

Curent Challenges in the Management of Patients with Follicular Lymphoma

CHAIRS: Efrat Luttwak, MD, MPH • Gilles Salles, MD, PhD

| 9:10 AM | Treatment Initiation Versus Active Surveillance Brian K. Link, MD |
|----------------|--|
| 9:40 AM | Histologic Transformation of Follicular Lymphoma Clémentine Sarkozy, MD, PhD |
| 10:10 ам | New Drugs on the Horizon for Follicular Lymphoma Andrew D. Zelenetz, MD, PhD |
| 10:30 AM | Panel Discussion |
| 10:50 ам | Break |

Advances in Therapeutic Strategies for Mantle Cell Lymphoma

CHAIR: Anita Kumar, MD

| 11:10 ам | Recent Insights Into Mantle Cell Lymphoma Biology TBA |
|----------|---|
| 11:25 ам | Current Dilemma in the First Line Therapy Setting Kami J. Maddocks, MD |
| 11:55 ам | Cellular Therapies in Mantle Cell Lymphoma Zachary Epstein-Peterson, MD |
| 12:10 рм | Panel Discussion |
| 12:30 pm | Lunch Break |

Hodgkin Lymphoma

CHAIR: Alison J. Moskowitz, MD

| 1:30 рм | KEYNOTE ADDRESS | | |
|---------|--|--|--|
| | Biology of Hodgkin Lymphoma Margaret A. Shipp, MD | | |
| 2:15 рм | The Evolving Standard of Care in First Line Robert Stuver, MD | | |
| 2:35 рм | Management of Older Patients Sarah Rutherford, MD | | |
| 2:55 рм | Options After First Line Treatment Failure Alison J. Moskowitz, MD | | |
| 3:15 рм | Panel Discussion | | |
| 3:35 рм | Break | | |
| | | | |

The Dark Side of B-Cells

CHAIRS: Sean E. Healton, MD, PhD • Andrew Intlekofer, MD

| | | Development breakout |
|---------|--|---|
| 3:55 рм | Germinal Center Biology | Session |
| | Laura Pasqualucci, MD | 3:55—6:15 рм |
| 4:25 рм | Notch and Marginal Zine Biology Ivan Maillard, MD, PhD | Further details and a full schedule will be shared soon |
| 4:55 рм | B-Cell Dynamics in the Germinal Center Coraline Mlynarczyk, PhD | |
| 5:25 рм | Single Cell Analyses of B-Cell Lymophoma Sandrine Roulland, PharmD, PhD | |
| 5:55 рм | Panel Discussion | |
| 6:10 рм | Closing Remarks and Adjourn Gilles Salles, MD, PhD | |

Empowering APPs and Nurses: Professional

Welcome Networking Reception

6:15-7:30 PM • Lobby

Join us for an opportunity to connect and interact with fellow attendees and faculty. Hors d'oeuvre and refreshments will be served.

Saturday • April 26

| Time | Session/Faculty |
|----------------|--|
| 7:30 AM | In-person Attendee Breakfast |
| 7:55 AM | Virtual Attendee Zoom Sign On |
| 8:00 am | Welcome and Introduction Gilles Salles, MD, PhD |

Improving Outcomes of Patients with T-Cell Lymphoma

CHAIR: Steven Horwitz, MD

| 8:05 AM | Advances in Biology Ting Zhou, MD |
|----------------|--|
| 8:20 AM | Optimizing First Line Therapy Barbara Pro, MD |
| 8:50 am | Advancing Therapeutic Options in the Relapse Setting Jasmine M. Zain, MD |
| 9:10 AM | Panel Discussion |
| 9:30 AM | Break |

Aggressive B-Cell Lymphoma: Addressing Remaining Gaps on the Path to a Definitive Cure

CHAIR: TBA

| 9:50 AM | Pogress in Large B-Cell Lymphoma Management Georg Lenz, MD |
|-----------------|---|
| 10:20 am | New Antibodies Engaging Immune Cells Lorenzo Falchi, MD |
| 10:40 am | Update on Primary Mediastinal B-Cell Lymphoma Raphael Steiner, MD |
| 10:55 ам | Update on Burkitt Lymphoma Ariela Noy, MD |
| 11:10 am | Panel Discussion |

Car T-Cell Therapies in Large B-Cell Lymphoma: Who, When, and How?

CHAIR: TBA

| 11:30 ам | Optimizing Patient Selection in 2025 Barbara Pro, MD | |
|----------|--|--|
| 11:50 ам | Radiation Therapy and CAR T Brandon Imber, MD, MA | |
| 12:10 рм | KEYNOTE ADDRESS Lessons and Challenges David G. Maloney, MD, PhD | |
| 12:55 рм | Panel Discussion | |
| 1:15 рм | Closing Remarks and Adjourn | |

Gilles Salles, MD, PhD

Farewell Lunch Reception

1:20-2:30 рм • Lobby

Join us for a final opportunity to network and connect with fellow attendees and faculty during a concluding luncheon.

Register by February 28 for early rates: msk.org/LymphomaSymposium

Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **13.25** *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC/CC RECOGNITION STATEMENTS

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

- 13.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program; and
- 13.25 Lifelong Learning (CME) credits in the American Board of Pathology's (**ABPath**) Continuing Certification program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABPath MOC/CC credit.

ANCC CNE STATEMENT

An application for NCPD credits is submitted.

Memorial Sloan Kettering Cancer Center adheres to the ACCME and ANCC's Standards for Integrity and Independence in Accredited Continuing Education. All relevant financial relationships have been mitigated prior to the commencement of the activity.



Memorial Sloan Kettering Cancer Center



Early rates available until February 28. Scan the QR code or visit:



msk.org/LymphomaSymposium

This symposium offers participants the choice of attending either in person or virtually. In-person registration includes continental breakfast, lunch, refreshment breaks, and a complimentary invitation to both the networking receptions.

Discounted registration is available for specific groups. Visit the symposium website for additional details.

| | Early* | General |
|---------------------------------------|---------------|---------|
| Physicians (MDs, PhDs, and DOs) | \$400 | \$450 |
| Advanced Practice Providers | \$150 | \$200 |
| Nurses and Other Healthcare Providers | \$100 | \$150 |
| Residents and Fellow** | \$50 | \$100 |
| Industry Professionals*** | n/a | \$785 |
| MSK Employees | Complimentary | |

*Apply promotion code **ERLYM25** during registration for early rates.

The resident and fellow rate is **non-refundable for in-person registration.

***An **"industry professional**" is defined as any individual, regardless of their profession type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company.

For details on our **cancellation terms**, visit the symposium website.



Memorial Sloan Kettering Cancer Center